Renaissance Technologies
ARTV

Renaissance Technologies’s Artiva Biotherapeutics ARTV Stock Holding History

Renaissance Technologies’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
151,000
+70,962
+89% +$646K ﹤0.01% 2137
2026
Q1 		$515K Sell
80,038
-36,162
-31% -$179K ﹤0.01% 2589
2025
Q4 		$498K Buy
116,200
+37,053
+47% +$140K ﹤0.01% 2578
2025
Q3 		$227K Buy
+79,147
New +$212K ﹤0.01% 3100

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Renaissance Technologies's ARTV Position: Q2 2026 in Review

Renaissance Technologies increased its Artiva Biotherapeutics (ARTV) stake by 89% in Q2 2026, buying an estimated $646K and bringing the position to 151,000 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2137.

Renaissance Technologies first reported a position in ARTV in Q3 2025 and has held it in 4 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Renaissance Technologies held 151,000 shares of Artiva Biotherapeutics worth $1.46M as of Q2 2026.
  • Renaissance Technologies bought 70,962 Artiva Biotherapeutics shares in Q2 2026, an estimated $646K.
  • Artiva Biotherapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2137 holding.
  • Renaissance Technologies first reported a position in Artiva Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.